The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade.
 
Emily Harrold
Consulting or Advisory Role - Pfizer
 
Zalak Patel
No Relationships to Disclose
 
Anna Maio
No Relationships to Disclose
 
Andrea Cercek
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen
 
Rona Yaeger
Consulting or Advisory Role - Array BioPharma; Mirati Therapeutics; Natera
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Neil Howard Segal
Consulting or Advisory Role - ABL Bio; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Revitope; Roche/Genentech
Research Funding - AstraZeneca; Bristol-Myers Squibb; Immunocore; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
 
Diane Lauren Reidy
Honoraria - Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Chiasma; ITM Oncologics; Lexicon
Research Funding - Ipsen; Merck; Novartis
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
 
Avni Mukund Desai
No Relationships to Disclose
 
Maria Isabel Carlo
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Alicia Latham
Other Relationship - Conquer Cancer Foundation
 
Ying L Liu
Research Funding - AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
 
Diana Mandelker
No Relationships to Disclose
 
Arnold Markowitz
No Relationships to Disclose
 
Kenneth Offit
Other Relationship - AnaNeo Therapeutics
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Innovatus Capital Partners; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Alcon (I); Gyroscope (I); Neurogene (I); Regenxbio (I)